{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:00:55Z","timestamp":1792036855198,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071974"],"award-info":[{"award-number":["82071974"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202225"],"award-info":[{"award-number":["82202225"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371998"],"award-info":[{"award-number":["82371998"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2022A0505050042"],"award-info":[{"award-number":["2022A0505050042"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangzhou Science and Technology Program","award":["202206010106"],"award-info":[{"award-number":["202206010106"]}]},{"name":"Guangzhou Science and Technology Program","award":["2023A03J0566"],"award-info":[{"award-number":["2023A03J0566"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00259-024-06907-3","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T06:02:27Z","timestamp":1726034547000},"page":"599-610","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Discovery of a highly specific radiolabeled antibody targeting B-cell maturation antigen: Applications in PET imaging of multiple myeloma"],"prefix":"10.1007","volume":"52","author":[{"given":"Jie","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjie","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyi","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8049-1991","authenticated-orcid":false,"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"key":"6907_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327.","journal-title":"Lancet"},{"key":"6907_CR2","doi-asserted-by":"crossref","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. Jama. 2022;327(5):464.","DOI":"10.1001\/jama.2022.0003"},{"key":"6907_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13:125.","journal-title":"J Hematol Oncol"},{"issue":"22","key":"6907_CR4","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti\u2013B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36(22):2267\u201380.","journal-title":"J Clin Oncol"},{"key":"6907_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"6907_CR6","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, et al. B cell maturation antigen\u2013specific CAR T cells are clinically active in multiple myeloma. J Clin Investig. 2019;129:2210\u201321.","journal-title":"J Clin Investig"},{"issue":"13","key":"6907_CR7","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128(13):1688\u2013700.","journal-title":"Blood"},{"key":"6907_CR8","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726\u201337.","journal-title":"N Engl J Med"},{"key":"6907_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"6907_CR10","doi-asserted-by":"crossref","unstructured":"Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA: A Cancer J Clin. 2018;68:471\u201387.","DOI":"10.3322\/caac.21493"},{"issue":"2","key":"6907_CR11","doi-asserted-by":"publisher","first-page":"e220859","DOI":"10.1148\/radiol.220859","volume":"306","author":"AS Parihar","year":"2023","unstructured":"Parihar AS, Hofman MS, Iravani A. 177Lu\u2013Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer. Radiology. 2023;306(2):e220859.","journal-title":"Radiology"},{"key":"6907_CR12","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.7150\/thno.19050","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Herrmann K, Schirbel A, H\u00e4nscheid H, L\u00fcckerath K, Schottelius M, et al. CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. Theranostics. 2017;7:1589\u201397.","journal-title":"Theranostics"},{"key":"6907_CR13","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2967\/jnumed.112.111997","volume":"54","author":"M Ch\u00e9rel","year":"2013","unstructured":"Ch\u00e9rel M, Gouard S, Gaschet J, Sa\u00ef-Maurel C, Bruchertseifer F, Morgenstern A, et al. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. J Nucl Med. 2013;54:1597\u2013604.","journal-title":"J Nucl Med"},{"key":"6907_CR14","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2967\/jnumed.119.239491","volume":"61","author":"I Quelven","year":"2020","unstructured":"Quelven I, Monteil J, Sage M, Saidi A, Mounier J, Bayout A, et al. 212Pb \u03b1-radioimmunotherapy targeting CD38 in multiple myeloma: A preclinical study. J Nucl Med. 2020;61:1058\u201365.","journal-title":"J Nucl Med"},{"key":"6907_CR15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.120.251983","volume":"62","author":"M Minnix","year":"2021","unstructured":"Minnix M, Adhikarla V, Caserta E, Poku E, Rockne R, Shively JE, et al. Comparison of CD38-targeted \u03b1-versus \u03b2-radionuclide therapy of disseminated multiple myeloma in an animal model. J Nucl Med. 2021;62:795\u2013801.","journal-title":"J Nucl Med"},{"key":"6907_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/0958-1669(94)90053-1","volume":"5","author":"MR Hurle","year":"1994","unstructured":"Hurle MR, Gross M. Protein engineering techniques for antibody humanization. Curr Opin Biotechnol. 1994;5:428\u201333.","journal-title":"Curr Opin Biotechnol"},{"key":"6907_CR17","doi-asserted-by":"crossref","unstructured":"Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R, et al. Antibody-drug conjugates: the new frontier of chemotherapy. Int J Mol Sci. 2020;21:5510.","DOI":"10.3390\/ijms21155510"},{"key":"6907_CR18","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415\u201322.","journal-title":"J Nucl Med"},{"key":"6907_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2967\/jnumed.119.233122","volume":"61","author":"T Watabe","year":"2020","unstructured":"Watabe T, Liu Y, Kaneda-Nakashima K, Shirakami Y, Lindner T, Ooe K, et al. Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu-and 225Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models. J Nucl Med. 2020;61:563\u20139.","journal-title":"J Nucl Med"},{"key":"6907_CR20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s00259-017-3803-4","volume":"45","author":"CG England","year":"2018","unstructured":"England CG, Jiang D, Ehlerding EB, Rekoske BT, Ellison PA, Hernandez R, et al. (89)Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging. 2018;45:110\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6907_CR21","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443\u20138.","journal-title":"Leukemia"},{"issue":"4","key":"6907_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood.2023021221","volume":"143","author":"L Rasche","year":"2024","unstructured":"Rasche L, Hudecek M, Einsele H. CAR T-cell therapy in multiple myeloma: mission accomplished? Blood. 2024;143(4):305\u201310.","journal-title":"Blood"},{"key":"6907_CR23","doi-asserted-by":"publisher","first-page":"116957","DOI":"10.1016\/j.bone.2023.116957","volume":"179","author":"ZM Zirakchian","year":"2024","unstructured":"Zirakchian ZM. The role of conventional and novel PET radiotracers in assessment of myeloma bone disease. Bone. 2024;179:116957.","journal-title":"Bone"},{"key":"6907_CR24","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","volume":"114","author":"TB Bartel","year":"2009","unstructured":"Bartel TB, Haessler J, Brown TLY, Shaughnessy JD, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068\u201376.","journal-title":"Blood"},{"key":"6907_CR25","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/leu.2009.89","volume":"23","author":"M Dimopoulos","year":"2009","unstructured":"Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia. 2009;23:1545\u201356.","journal-title":"Leukemia"},{"key":"6907_CR26","doi-asserted-by":"publisher","first-page":"12806","DOI":"10.1073\/pnas.1509667112","volume":"112","author":"H Luo","year":"2015","unstructured":"Luo H, Hernandez R, Hong H, Graves SA, Yang Y, England CG, et al. Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry. Proc Natl Acad Sci. 2015;112:12806\u201311.","journal-title":"Proc Natl Acad Sci"},{"issue":"21","key":"6907_CR27","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang D, Wang J, Hu G, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood. 2021;137(21):2890\u2013901.","journal-title":"Blood"},{"key":"6907_CR28","doi-asserted-by":"publisher","first-page":"108106","DOI":"10.1016\/j.pharmthera.2021.108106","volume":"236","author":"C Ceci","year":"2022","unstructured":"Ceci C, Lacal PM, Graziani G. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential. Pharmacol Ther. 2022;236:108106.","journal-title":"Pharmacol Ther."},{"key":"6907_CR29","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.2967\/jnumed.123.266313","volume":"64","author":"T Watabe","year":"2023","unstructured":"Watabe T, Kabayama K, Naka S, Yamamoto R, Kaneda K, Serada S, et al. Immuno-PET and Targeted \u03b1-Therapy Using Anti\u2013Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma. J Nucl Med. 2023;64:1949\u201355.","journal-title":"J Nucl Med"},{"key":"6907_CR30","doi-asserted-by":"publisher","first-page":"20806","DOI":"10.1021\/acs.inorgchem.3c02714","volume":"62","author":"AK Salih","year":"2023","unstructured":"Salih AK, Dominguez Garcia M, Raheem SJ, Ahiahonu WK, Price EW. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals. Inorg Chem. 2023;62:20806\u201319.","journal-title":"Inorg Chem"},{"issue":"10","key":"6907_CR31","doi-asserted-by":"publisher","first-page":"7077","DOI":"10.1007\/s00330-023-09679-w","volume":"33","author":"Y Kong","year":"2023","unstructured":"Kong Y, Xie F, Zhang Z, Wang S, Zhang Y, Di Y, et al. Evaluation of novel anti-CEACAM6 antibody-based conjugates for radioimmunotheranostics of pancreatic ductal adenocarcinoma. Eur Radiol. 2023;33(10):7077\u201388.","journal-title":"Eur Radiol."},{"key":"6907_CR32","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1021\/acs.molpharmaceut.1c00628","volume":"19","author":"W Wei","year":"2022","unstructured":"Wei W, Zhang Y, Zhang D, Liu Q, An S, Chen Y, et al. Annotating BCMA expression in multiple myelomas. Mol Pharm. 2022;19:3492\u2013501.","journal-title":"Mol Pharm"},{"key":"6907_CR33","doi-asserted-by":"publisher","first-page":"e2101565","DOI":"10.1002\/adhm.202101565","volume":"11","author":"E Thomas","year":"2022","unstructured":"Thomas E, Mathieu C, Moreno-Gaona P, Mittelheisser V, Lux F, Tillement O, et al. Anti-BCMA Immuno-NanoPET Radiotracers for Improved Detection of Multiple Myeloma. Adv Healthc Mater. 2022;11:e2101565.","journal-title":"Adv Healthc Mater"},{"key":"6907_CR34","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s00259-023-06575-9","volume":"51","author":"Q Yang","year":"2024","unstructured":"Yang Q, Chen Z, Qiu Y, Huang W, Wang T, Song L, et al. Theranostic role of (89)Zr- and (177)Lu-labeled aflibercept in breast cancer. Eur J Nucl Med Mol Imaging. 2024;51:1246\u201360.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6907_CR35","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.2967\/jnumed.123.266313","volume":"64","author":"T Watabe","year":"2023","unstructured":"Watabe T, Kabayama K, Naka S, Yamamoto R, Kaneda K, Serada S, et al. Immuno-PET and Targeted \u03b1-Therapy Using Anti-Glypican-1 Antibody Labeled with (89)Zr or (211)At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma. J Nucl Med. 2023;64:1949\u201355.","journal-title":"J Nucl Med"},{"key":"6907_CR36","doi-asserted-by":"crossref","unstructured":"Chen Y, Hou X, Li D, Ding J, Liu J, Wang Z, et al. Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors. J Pharm Anal. 2023;13:367\u201375.","DOI":"10.1016\/j.jpha.2023.02.011"},{"key":"6907_CR37","doi-asserted-by":"publisher","first-page":"108106","DOI":"10.1016\/j.pharmthera.2021.108106","volume":"236","author":"C Ceci","year":"2022","unstructured":"Ceci C, Lacal PM, Graziani G. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential. Pharmacol Ther. 2022;236:108106.","journal-title":"Pharmacol Ther"},{"key":"6907_CR38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2015.12.003","volume":"109","author":"S Aghevlian","year":"2017","unstructured":"Aghevlian S, Boyle AJ, Reilly RM. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting \u03b1-particles or Auger electrons. Adv Drug Deliv Rev. 2017;109:102\u201318.","journal-title":"Adv Drug Deliv Rev"},{"key":"6907_CR39","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/ijc.30500","volume":"140","author":"P Bhusari","year":"2016","unstructured":"Bhusari P, Vatsa R, Singh G, Parmar M, Bal A, Dhawan DK, et al. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients. Int J Cancer. 2016;140:938\u201347.","journal-title":"Int J Cancer"},{"key":"6907_CR40","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.2967\/jnumed.115.168443","volume":"57","author":"RP Baum","year":"2016","unstructured":"Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006\u201313.","journal-title":"J Nucl Med"},{"key":"6907_CR41","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.118.230607","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS\/SNMMI procedure standard for somatostatin receptor\u2013based peptide receptor radionuclide therapy with 177Lu-DOTATATE. J Nucl Med. 2019;60:937\u201343.","journal-title":"J Nucl Med"},{"key":"6907_CR42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrc3925","volume":"15","author":"SM Larson","year":"2015","unstructured":"Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347\u201360.","journal-title":"Nat Rev Cancer"},{"key":"6907_CR43","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-23-2130","volume":"30","author":"A Wadhwa","year":"2024","unstructured":"Wadhwa A, Wang S, Pati\u00f1o-Escobar B, Bidkar AP, Bobba KN, Chan E, et al. CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma. Clin Cancer Res. 2024;30:1009\u201321.","journal-title":"Clin Cancer Res"},{"key":"6907_CR44","doi-asserted-by":"publisher","first-page":"4749","DOI":"10.2147\/DDDT.S279054","volume":"14","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Huang N, Xu J, Zheng W, Cui X. Homoharringtonine exerts an antimyeloma effect by promoting excess parkin-dependent mitophagy. Drug Des Dev Ther. 2020;14:4749\u201363.","journal-title":"Drug Des Dev Ther"},{"key":"6907_CR45","doi-asserted-by":"publisher","first-page":"11593","DOI":"10.1038\/s41598-024-62298-3","volume":"14","author":"D Zhang","year":"2024","unstructured":"Zhang D, Zhan D, Zhang R, Sun Y, Duan C, Yang J, et al. Treg-derived TGF-\u03b21 dampens cGAS-STING signaling to downregulate the expression of class I MHC complex in multiple myeloma. Sci Rep. 2024;14:11593.","journal-title":"Sci Rep"},{"issue":"2","key":"6907_CR46","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2967\/jnumed.117.196063","volume":"59","author":"A Ghai","year":"2018","unstructured":"Ghai A, Maji D, Cho N, Chanswangphuwana C, Rettig M, Shen D, et al. Preclinical development of CD38-targeted [89Zr] Zr-DFO-daratumumab for imaging multiple myeloma. J Nucl Med. 2018;59(2):216\u201322.","journal-title":"J Nucl Med"},{"issue":"5","key":"6907_CR47","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.nucmedbio.2010.12.011","volume":"38","author":"DS Abou","year":"2011","unstructured":"Abou DS, Ku T, Smith-Jones PM. In vivo biodistribution and accumulation of 89Zr in mice. Nucl Med Biol. 2011;38(5):675\u201381.","journal-title":"Nucl Med Biol"},{"issue":"5","key":"6907_CR48","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/clpt.2010.12","volume":"87","author":"EC Dijkers","year":"2010","unstructured":"Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr\u2010trastuzumab and PET imaging of HER2\u2010positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87(5):586\u201392.","journal-title":"Clin Pharmacol Ther"},{"key":"6907_CR49","doi-asserted-by":"crossref","unstructured":"Yeh R, O\u2019Donoghue JA, Jayaprakasam VS, Mauguen A, Min R, Park, et al. First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer. J Nucl Med. 2024;65(3):386\u2013393.","DOI":"10.2967\/jnumed.123.266392"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06907-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06907-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06907-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T10:21:10Z","timestamp":1736850070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06907-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["6907"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06907-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"assertion":[{"value":"6 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}